You are here

Study Confirms Link Between Omega-3 Fatty Acids and Increased Risk of Prostate Cancer

Consumption of fatty fish and fish-oil supplements linked to 71% higher risk (July 11)

A second prospective study by scientists at the Fred Hutchison Cancer Research Center in Seattle, Wash., has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Published in the online edition of the Journal of the National Cancer Institute, the latest findings indicate that high concentrations of EPA, DPA, and DHA — the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish-oil supplements — are associated with a 71% increased risk of high-grade prostate cancer. The study also found a 44% increase in the risk for low-grade prostate cancer and an overall 43% increase in the risk for all prostate cancers.

The increase in risk for high-grade prostate cancer is important because those tumors are more likely to be fatal, the report says.

The findings confirm a 2011 study published by the same scientific team that reported a similar link between high blood concentrations of DHA and a more than doubling of the risk for developing high-grade prostate cancer. The latest study also confirms results from a large European study.

“The consistency of these findings suggests that these fatty acids are involved in prostate tumorigenesis, and recommendations to increase long-chain omega-3 fatty acid intake, in particular through supplementation, should consider its potential risks,” the authors wrote.

Sources: Fred Hutchison Cancer Research Center; July 11, 2013; and JNCI; July 10, 2013.

Recent Headlines

Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function